Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study.

Ferrières J, Dallongeville J, Rossignol M, Bénichou J, Caro JJ, Getsios D, Hernandez L, Abenhaim L, Grimaldi-Bensouda L.

J Clin Lipidol. 2016 Nov - Dec;10(6):1379-1388. doi: 10.1016/j.jacl.2016.08.015. Epub 2016 Sep 7.

PMID:
27919355
2.

Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease.

Hernandez L, Ozen A, DosSantos R, Getsios D.

Pharmacoeconomics. 2016 Jul;34(7):681-707. doi: 10.1007/s40273-016-0392-1. Review.

PMID:
26899832
3.

Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.

Saint-Laurent Thibault C, Özer Stillman I, Chen S, Getsios D, Proskorovsky I, Hernandez L, Dixit S.

J Med Econ. 2015;18(11):930-43. doi: 10.3111/13696998.2015.1063501. Epub 2015 Aug 26.

PMID:
26086535
4.

Evaluating disease-modifying agents: a simulation framework for Alzheimer's disease.

Guo S, Getsios D, Revankar N, Xu P, Thompson G, Bobula J, Lacey L, Gaudig M.

Pharmacoeconomics. 2014 Nov;32(11):1129-39. doi: 10.1007/s40273-014-0203-5.

PMID:
25124747
5.

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis.

Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M.

Clinicoecon Outcomes Res. 2014 Apr 1;6:141-9. doi: 10.2147/CEOR.S55095. eCollection 2014.

6.

Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.

Getsios D, Marton JP, Revankar N, Ward AJ, Willke RJ, Rublee D, Ishak KJ, Xenakis JG.

Pharmacoeconomics. 2013 Sep;31(9):767-80. doi: 10.1007/s40273-013-0070-5.

PMID:
23821436
7.

Improved perioperative blood pressure control leads to reduced hospital costs.

Getsios D, Wang Y, Stolar M, Williams G, Ishak KJ, Hu MY, Alvarez P, Crothers TA.

Expert Opin Pharmacother. 2013 Jul;14(10):1285-93. doi: 10.1517/14656566.2013.798646. Epub 2013 May 8.

PMID:
23656583
8.

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps.

Guo S, Getsios D, Hernandez L, Cho K, Lawler E, Altincatal A, Lanes S, Blankenburg M.

Int J Alzheimers Dis. 2012;2012:548157. doi: 10.1155/2012/548157. Epub 2012 Dec 26.

9.

Accounting for the relationship between per diem cost and LOS when estimating hospitalization costs.

Ishak KJ, Stolar M, Hu MY, Alvarez P, Wang Y, Getsios D, Williams GC.

BMC Health Serv Res. 2012 Dec 1;12:439. doi: 10.1186/1472-6963-12-439.

10.

Inclusion of compliance and persistence in economic models: past, present and future.

Kadambi A, Leipold RJ, Kansal AR, Sorensen S, Getsios D.

Appl Health Econ Health Policy. 2012 Nov 1;10(6):365-79. doi: 10.2165/11640590-000000000-00000. Review.

PMID:
23030640
11.

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.

Hartz S, Getsios D, Tao S, Blume S, Maclaine G.

BMC Neurol. 2012 Feb 8;12:2. doi: 10.1186/1471-2377-12-2.

12.

An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.

Getsios D, Blume S, Ishak KJ, Maclaine G, Hernández L.

Alzheimers Dement. 2012 Jan;8(1):22-30. doi: 10.1016/j.jalz.2010.07.001. Epub 2011 Mar 21.

PMID:
21420366
13.

Discrete event simulation: the preferred technique for health economic evaluations?

Caro JJ, Möller J, Getsios D.

Value Health. 2010 Dec;13(8):1056-60. doi: 10.1111/j.1524-4733.2010.00775.x. Epub 2010 Sep 3.

14.

Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.

Getsios D, Blume S, Ishak KJ, Maclaine GD.

Pharmacoeconomics. 2010;28(5):411-27. doi: 10.2165/11531870-000000000-00000.

PMID:
20402542
15.

Underestimation of invasive meningococcal disease case fatality rates.

Crépey P, Getsios D.

Clin Infect Dis. 2009 Oct 1;49(7):1136-7; author reply 1137. doi: 10.1086/605599. No abstract available.

PMID:
19739964
16.

Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects.

Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, Nguyen VH.

PLoS One. 2009 Jul 16;4(7):e6284. doi: 10.1371/journal.pone.0006284.

17.

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Getsios D, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2007;25(12):997-1006. Review.

PMID:
18047386
18.

Regarding probabilistic analysis and computationally expensive models: necessary and required?

Caro JJ, Getsios D, Möller J.

Value Health. 2007 Jul-Aug;10(4):317-8; author reply 319. No abstract available.

19.

Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.

Caro JJ, Möller J, Getsios D, Coudeville L, El-Hadi W, Chevat C, Nguyen VH, Caro I.

BMC Public Health. 2007 Jun 29;7:130.

20.

Oxybutynin extended release and tolterodine immediate release : a health economic comparison.

Getsios D, Caro JJ, Ishak KJ, El-Hadi W, Payne K, O'connel M, Albrecht D, Feng W, Dubois D.

Clin Drug Investig. 2004;24(2):81-8.

PMID:
17516694
21.

Managing meningococcal disease in the United States: Hospital case characteristics and costs by age.

O'Brien JA, Caro JJ, Getsios D.

Value Health. 2006 Jul-Aug;9(4):236-43.

22.

Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.

Getsios D, El-Hadi W, Caro I, Caro JJ.

Pharmacoeconomics. 2005;23(10):995-1006. Review.

PMID:
16235973
23.

Pertussis immunization of adolescents in the United States: an economic evaluation.

Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA.

Pediatr Infect Dis J. 2005 May;24(5 Suppl):S75-82.

PMID:
15876932
24.

Economic burden of pertussis and the impact of immunization.

Caro JJ, Getsios D, Payne K, Annemans L, Neumann PJ, Trindade E.

Pediatr Infect Dis J. 2005 May;24(5 Suppl):S48-54. Review.

PMID:
15876924
25.

Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.

Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA.

Diabet Med. 2004 Nov;21(11):1229-36.

PMID:
15498090
26.

Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research.

Getsios D, Caro I, El-Hadi W, Caro JJ.

Int J Technol Assess Health Care. 2004 Summer;20(3):280-8. Review.

PMID:
15446757
27.

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F.

Drugs Aging. 2004;21(10):677-86.

PMID:
15287825
28.
29.

Economic assessments of low molecular weight heparin in venous thromboembolism.

Ward A, Getsios D, O'Brien J, Caro JJ.

Expert Rev Pharmacoecon Outcomes Res. 2004 Feb;4(1):39-47. doi: 10.1586/14737167.4.1.39.

PMID:
19807334
30.

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis.

Caro J, Getsios D, Migliaccio-Walle K, Ishak J, El-Hadi W; AHEAD Study Group.

BMC Geriatr. 2003 Dec 15;3:6.

31.

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.

Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R; AHEAD Study Group.

Int J Geriatr Psychiatry. 2003 Aug;18(8):740-7.

PMID:
12891643
32.

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G; AHEAD Study Group.

Clin Ther. 2003 Jun;25(6):1806-25.

PMID:
12860500
33.

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

Caro J, Ward A, Ishak K, Migliaccio-Walle K, Getsios D, Papadopoulos G, Torfs K.

BMC Neurol. 2002 Aug 19;2:6.

34.

Instituting a routine varicella vaccination program in Canada: an economic evaluation.

Getsios D, Caro JJ, Caro G, De Wals P, Law BJ, Robert Y, Lance JM.

Pediatr Infect Dis J. 2002 Jun;21(6):542-7.

PMID:
12182379
35.

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.

Caro JJ, Salas M, Ward A, Getsios D, Mehnert A; AHEAD Study Group. Assessment of Health Economics in Alzheimer's Disease.

Dement Geriatr Cogn Disord. 2002;14(2):84-9.

PMID:
12145455
36.

Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B.

Pharmacoeconomics. 2002;20(9):629-37.

PMID:
12141890
37.

Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.

Caro JJ, Getsios D, Caro I, O'Brien JA.

Pharmacoeconomics. 2002;20(9):593-602.

PMID:
12141887
38.

Pharmacoeconomic evidence and considerations for triptan treatment of migraine.

Caro JJ, Getsios D.

Expert Opin Pharmacother. 2002 Mar;3(3):237-48. Review.

PMID:
11866674
39.

Diabetes in Canada: direct medical costs of major macrovascular complications.

O'Brien JA, Caro I, Getsios D, Caro JJ.

Value Health. 2001 May-Jun;4(3):258-65. Review.

40.

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada.

Getsios D, Caro JJ, Caro G, Ishak K; AHEAD Study Group.

Neurology. 2001 Sep 25;57(6):972-8.

PMID:
11571319
41.

Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care.

Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G, Ward A; AHEAD Study Group.

Neurology. 2001 Sep 25;57(6):964-71.

PMID:
11571318
42.

Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis.

Caro JJ, Getsios D, Raggio G, Caro G, Black L.

Headache. 2001 May;41(5):456-64.

PMID:
11380643
43.

Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis.

Caro G, Getsios D, Caro JJ, Raggio G, Burrows M, Black L.

Cephalalgia. 2001 Feb;21(1):12-9.

PMID:
11298658
44.

The migraine ACE model: evaluating the impact on time lost and medical resource Use.

Caro JJ, Caro G, Getsios D, Raggio G, Burrows M, Black L.

Headache. 2000 Apr;40(4):282-91.

PMID:
10759932

Supplemental Content

Loading ...
Support Center